TESTOSTERONE UNDECANOATE - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for testosterone undecanoate and what is the scope of patent protection?

Testosterone undecanoate is the generic ingredient in four branded drugs marketed by Tolmar, Marius Pharms Llc, Verity, and Endo Operations, and is included in four NDAs. There are twenty-nine patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Testosterone undecanoate has one hundred and thirty-seven patent family members in thirty-nine countries.

There are seven drug master file entries for testosterone undecanoate. Six suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for TESTOSTERONE UNDECANOATE

International Patents:	137
US Patents:	29
Tradenames:	4
Applicants:	4
NDAs:	4
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	51
Clinical Trials:	59
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TESTOSTERONE UNDECANOATE
What excipients (inactive ingredients) are in TESTOSTERONE UNDECANOATE?	TESTOSTERONE UNDECANOATE excipients list
DailyMed Link:	TESTOSTERONE UNDECANOATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TESTOSTERONE UNDECANOATE

Generic Entry Dates for TESTOSTERONE UNDECANOATE^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up Dosage: CAPSULE;ORAL
Generic Entry Dates for TESTOSTERONE UNDECANOATE^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up Dosage: INJECTABLE;INTRAMUSCULAR
Generic Entry Dates for TESTOSTERONE UNDECANOATE^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: NEW PRODUCT Dosage: CAPSULE;ORAL
Generic Entry Dates for TESTOSTERONE UNDECANOATE^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: NEW PRODUCT Dosage: CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TESTOSTERONE UNDECANOATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Morten Hostrup, PhD	N/A
Norwegian School of Sport Sciences	Phase 2/Phase 3
Oslo University Hospital	Phase 2/Phase 3

See all TESTOSTERONE UNDECANOATE clinical trials

Generic filers with tentative approvals for TESTOSTERONE UNDECANOATE

Applicant	Application No.	Strength	Dosage Form
⤷ Sign Up	⤷ Sign Up	750MG/3ML (250MG/ML)	INJECTABLE;INTRAMUSCULAR

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for TESTOSTERONE UNDECANOATE

Drug Class	Androgen
Mechanism of Action	Androgen Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for TESTOSTERONE UNDECANOATE

G03BA	3-oxoandrosten (4) derivatives
G03B	ANDROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for TESTOSTERONE UNDECANOATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVEED	Injection	testosterone undecanoate	250 mg/mL	022219	1	2014-06-11

US Patents and Regulatory Information for TESTOSTERONE UNDECANOATE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-002	Mar 27, 2019		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Verity	TLANDO	testosterone undecanoate	CAPSULE;ORAL	208088-001	Mar 28, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Marius Pharms Llc	KYZATREX	testosterone undecanoate	CAPSULE;ORAL	213953-002	Jul 27, 2022		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Verity	TLANDO	testosterone undecanoate	CAPSULE;ORAL	208088-001	Mar 28, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-003	Mar 27, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-003	Mar 27, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for TESTOSTERONE UNDECANOATE

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Uruguay	35445	ÉSTERES DE TESTOSTERONA DE CADENA LARGA LIPOEQUILIBRADOS PARA LA ADMINISTRACIÓN ORAL	⤷ Sign Up
Montenegro	P14508	POSTUPCI I FARMACEUTSKI SASTAVI ZA POUZDANO POSTIZANJE PRIHVATLJIVIH NIVOA SERUMA TESTOSTERONA (METHODS AND PHARMACEUTICAL COMPOSITIONS FOR RELIABLE ACHIEVEMENT OF ACCEPTABLE SERUM TESTOSTERONE LEVELS)	⤷ Sign Up
Spain	2271772		⤷ Sign Up
European Patent Office	1871384		⤷ Sign Up
Australia	2014232475	Lipobalanced long chain testosterone esters for oral delivery	⤷ Sign Up
China	101217963	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.